First author [Ref.] | Population | Patients n | Treatment groups | History of asthma n (%) | Treatment duration | Outcome |
Ädelroth [28] | SAR (birch pollen) | 251 | Omalizumab | 85 (34) | Birch pollen season | Daily nasal symptom severity score: omalizumab 0.70, placebo 0.98, p<0.01 |
Placebo | ||||||
Casale [51] | SAR (ragweed pollen) | 536 | Omalizumab 300, 150 or 50 mg | 137 (26) | Ragweed pollen season | Daily nasal symptom severity score: omalizumab 300 mg 0.75, 150 mg 0.86, 50 mg 0.88, placebo 0.98, p = 0.02 for 300 mg dose versus placebo |
Placebo | ||||||
Chervinsky [52] | PAR | 289 | Omalizumab | 76 (26) | 16 weeks | Daily nasal symptom severity score: omalizumab 0.99, placebo 1.3, p<0.001 |
Placebo | ||||||
Hanf [50] | AR | 23 | Omalizumab | Not available | 16 weeks | Allergen-challenge nasal symptom score: |
Placebo | omalizumab reduced nasal symptom score compared with baseline and placebo (p<0.01). | |||||
Vignola [9] | Moderate/severe asthma and persistent allergic rhinitis | 405 | Omalizumab | 405 (100) | 28 weeks | Omalizumab reduced Wasserfallen rhinitis score by 3.5 compared with placebo (p<0.001) |
Placebo |
SAR: seasonal allergic rhinitis; PAR: perennial allergic rhinitis; AR: allergic rhinitis.